ALSO NOTED: ReNeuron returns to market; Scientists urge Relenza stockpiles; CombiMatrix, Arizona State collaborate; and much mo

> ReNeuron, which works with adult stem cells, has returned to London's junior AIM market after a two-year absence. Story

> In an article in The Lancet, scientists are urging governments to stockpile GSK's Relenza to guard against an avian flu epidemic. Report

> Xenogen of Alameda, California, will raise $15 million in a private placement of common stock. Release

> CombiMatrix and the BioDesign Institute at Arizona State University will collaborate on a peptide array synthesizer. Release

And Finally… Nearly one-in-six US high school students suffer from asthma, according to a new federal study that suggests better ways to control the chronic lung condition. Article

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.